Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Gynecologic Malignancies & Cognitive Deficit

Gynecol Oncol; ePub 2016 Mar 2; Van Arsdale, Rosenbaum, et al

A high prevalence of cognitive deficit exists in women with gynecologic malignancies, with age, race, education, cancer site and pain also associated with decreased cognition. This according to a study of 165 women at an urban ambulatory gynecologic oncology facility who were questioned using a Montreal Cognitive Assessment (MoCA) among other tools. Researchers found:

• The mean MoCA score for the entire cohort was 24.1.

• 24% of patients had MoCA scores <22.

• 60% of women with gynecologic cancers had decreased cognition by MoCA screening.

• Low scores of <22 were associated with older age, non-white race/ethnicity, lower education level, uterine and vulvar cancers, and pain ≥5.

• There was a trend toward lower cognition scores for women treated with both chemotherapy and radiation.

• There was no association of pain with use of opioid pain medication and low cognition scores.

Citation: Van Arsdale A, Rosenbaum D, Kaur G, Pinto P, et al. Prevalence and factors associated with cognitive deficit in women with gynecologic malignancies. [Published online ahead of print March 2, 2016]. Gynecol Oncol. doi:http://dx.doi.org/10.1016/j.ygyno.2016.03.001.